Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

被引：0
|
作者：
Berenson, James R.
Yellin, Ori
Bessudo, Alberto [1 ]
Boccia, Ralph V. [2 ]
Noga, Stephen J. [3 ]
Gravenor, Donald S. [4 ]
Patel-Donnelly, Dipti [5 ]
Siegel, Robert S. [6 ]
Kewalramani, Tarun [7 ]
Gorak, Edward J. [8 ]
Swift, Regina A. [9 ]
Mayo, Debra [10 ]
机构：
[1] San Diego Pacific Oncol Hematol Associates Inc, Encinitas, CA USA
[2] Ctr Canc & Blood Disorders, Bethesda, MD USA
[3] Weinberg Canc Inst Franklin Sq, Sect Hematol, Baltimore, MD USA
[4] Family Canc Ctr, Memphis, TN USA
[5] Virginia Canc Specialists PC, Fairfax, VA USA
[6] George Washington Univ, Med Ctr, Washington, DC 20037 USA
[7] Lahey Clin Med Ctr, Burlington, MA 01803 USA
[8] Geisinger Med Ctr, Danville, PA 17822 USA
[9] James R Berenson MD Inc, Los Angeles, CA USA
[10] Cephalon Inc, Frazer, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：808 / 809
页数：2
相关论文
共 50 条
  • [1] An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph
    Gravenor, Donald S.
    Noga, Stephen
    Siegel, Robert S.
    Swift, Regina A.
    Ehrman, Michael D.
    Bensen-Kennedy, Debra
    BLOOD, 2010, 116 (21) : 1261 - 1261
  • [2] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Moll, Barbara
    Heyn, Simone
    Jaekel, Nadja
    Wagner, Ina
    Rohrberg, Robert
    Hurtz, Hans-Juergen
    Schmalfeld, Marion
    Assmann, Michael
    Edelmann, Thomas
    Mohren, Martin
    Hoffmann, Franz Albert
    Becker, Cornelia
    Schwarzer, Andreas
    Schoenfelder, Uta
    Zehrfeld, Thomas
    Hensel, Gerald
    Loeschcke, Kerstin
    Krahl, Rainer
    Al Ali, Haifa
    Niederwieser, Dietger
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 499 - 508
  • [3] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Wolfram Pönisch
    Malvina Bourgeois
    Barbara Moll
    Simone Heyn
    Nadja Jäkel
    Ina Wagner
    Robert Rohrberg
    Hans-Jürgen Hurtz
    Marion Schmalfeld
    Michael Aßmann
    Thomas Edelmann
    Martin Mohren
    Franz Albert Hoffmann
    Cornelia Becker
    Andreas Schwarzer
    Uta Schönfelder
    Thomas Zehrfeld
    Gerald Hensel
    Kerstin Löschcke
    Rainer Krahl
    Haifa Al Ali
    Dietger Niederwieser
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 499 - 508
  • [4] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [5] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [6] Bortezomib in combination with bendamustine and preduisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Wang, Song-Yau
    Heyn, Simone F.
    Jaekel, Nadja
    Braunert, Leanthe
    Rohrberg, Robert
    Hurtz, Hans Juergen
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Becker, Cornelia
    Al Ali, Haifa
    Niederwieser, Dietger W.
    BLOOD, 2007, 110 (11) : 799A - 800A
  • [7] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Szatrowski, T.
    Kaplita, S.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
  • [8] Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Akos
    Bruns, Ingmar
    Neumann, Frank
    Fenk, Barbara
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2345 - 2351
  • [9] Bendamustine and prednisone in combination with Bortezomib in the treatment of patients with relapsed/refractory multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Heyn, S.
    Wagner, I
    Jaekel, N.
    Rohrberg, R.
    Hurtz, H. -J.
    Schmalfeld, M.
    Assmann, M.
    Edelmann, T.
    Mohren, M.
    Hoffmann, F. A.
    Schwarzer, A.
    Hensel, G.
    Loeschke, K.
    Becker, C.
    Krahl, R.
    Al-Ali, H. K.
    Niederwieser, D.
    ONKOLOGIE, 2012, 35 : 144 - 144
  • [10] Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Wang, S. Y.
    Heyn, S.
    Jaekel, N.
    Al Ali, H.
    Niederwieser, D.
    ONKOLOGIE, 2008, 31 : 136 - 136
12345